1. Home
  2. IHT vs NEUP Comparison

IHT vs NEUP Comparison

Compare IHT & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InnSuites Hospitality Trust Shares of Beneficial Interest

IHT

InnSuites Hospitality Trust Shares of Beneficial Interest

HOLD

Current Price

$1.40

Market Cap

11.3M

Sector

Finance

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.45

Market Cap

10.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
IHT
NEUP
Founded
1971
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
11.3M
10.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IHT
NEUP
Price
$1.40
$4.45
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
19.7K
112.7K
Earning Date
12-19-2025
11-14-2025
Dividend Yield
1.43%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,463,789.00
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.25
$2.90
52 Week High
$4.24
$21.40

Technical Indicators

Market Signals
Indicator
IHT
NEUP
Relative Strength Index (RSI) 50.89 39.33
Support Level $1.25 $4.10
Resistance Level $1.49 $4.65
Average True Range (ATR) 0.07 0.26
MACD 0.02 0.24
Stochastic Oscillator 65.47 50.91

Price Performance

Historical Comparison
IHT
NEUP

About IHT InnSuites Hospitality Trust Shares of Beneficial Interest

InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: